By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

TG Therapeutics, Inc. 

787 Seventh Avenue
48th Floor
New York  New York  10019  U.S.A.
Phone: 212-554-4484 Fax: 212-554-4531


SEARCH JOBS


Industry
Pharmaceutical






Company News
TG Therapeutics, Inc. (MHA) To Provide An Update On Its Clinical Programs And Corporate Goals For 2015 At The 33rd Annual J.P. Morgan Healthcare Conference 1/15/2015 7:11:52 AM
TG Therapeutics, Inc. (MHA) To Present At The 33rd Annual J.P. Morgan Healthcare Conference 1/8/2015 12:29:22 PM
TG Therapeutics, Inc. (MHA) Announces Appointment Of Kenneth Hoberman To Board Of Directors 12/17/2014 7:45:45 AM
TG Therapeutics, Inc. (MHA) Release: Preliminary Data From Ongoing Phase I/II Dose Escalation Study Of TG-1101 (Ublituximab) In Combination With TGR-1202 In Heavily Pre-Treated Relapsed/Refractory B-Cell Malignancies Demonstrates Encouraging Clinical Activity And Safety 12/9/2014 10:49:31 AM
TG Therapeutics, Inc. (MHA) Release: Data From Phase 2 Clinical Trial Of TG-1101 (Ublituximab) And Ibrutinib Shows Compelling Clinical Activity In Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL) 12/9/2014 10:37:35 AM
TG Therapeutics, Inc. (MHA) Release: Interim Data From Phase 1 Dose Escalation Clinical Trial Of TGR-1202, The Once-Daily PI3K Delta Inhibitor, Demonstrates Significant Clinical Activity And Lack Of Hepatic Toxicity In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia And Non-Hodgkin's Lymphoma 12/8/2014 7:24:52 AM
TG Therapeutics, Inc. (MHA) Announces Collaboration For A Clinical Trial Of TGR-1202 In Combination With Ibrutinib (Imbruvica) For Patients With Select B-Cell Malignancies 12/1/2014 10:32:34 AM
TG Therapeutics, Inc. (MHA) To Present At The 2014 Deutsche Bank (DB) BioFEST Conference 11/26/2014 11:52:36 AM
TG Therapeutics, Inc. (MHA) Announces Third Quarter 2014 Financial Results and Business Update 11/11/2014 8:06:27 AM
TG Therapeutics, Inc. (MHA) To Host Conference Call On Third Quarter 2014 Financial Results And Business Update 11/10/2014 7:42:10 AM
12345678910...
//-->